医学
结直肠癌
放化疗
新辅助治疗
肿瘤科
化疗
远处转移
内科学
病态的
全直肠系膜切除术
癌症
直肠
转移
外科
乳腺癌
作者
Swapnil Patel,Akhil Kapoor
出处
期刊:Lancet Oncology
[Elsevier BV]
日期:2021-07-01
卷期号:22 (7): e301-e301
被引量:1
标识
DOI:10.1016/s1470-2045(21)00304-1
摘要
In the era of preoperative chemoradiotherapy and MRI-directed, good-quality rectal cancer surgery, strategies for mitigating distant failures (often as high as 25%) and providing robust organ preservation are highly needed. With the UNICANCER-PRODIGE 23 trial,1 Thierry Conroy and colleagues have provided practice-changing evidence in favour of total neoadjuvant therapy with a 7% benefit in 3-year metastasis-free survival (79% in the neoadjuvant chemotherapy group vs 72% in the standard-of-care group) and a high pathological complete response rate of 28%.
科研通智能强力驱动
Strongly Powered by AbleSci AI